Phase III trials in oncology: Setting standards of care?

Nature Clinical Practice Oncology

Volumn 2, Issue 9, 2005, Pages 426-427

  Seeber, Siegfried ^a   Braun, Ada M ^a,b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PREDNISONE; TOPOTECAN; TRASTUZUMAB;

ADVANCED CANCER; BREAST CANCER; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL RESEARCH; CLINICAL TRIAL; COLORECTAL CANCER; DRUG DOSE REGIMEN; EVIDENCE BASED MEDICINE; HUMAN; INOPERABLE CANCER; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; OVARY CANCER; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II; HUMANS; MEDICAL ONCOLOGY; NEOPLASM METASTASIS; NEOPLASMS; PROGNOSIS; QUALITY OF HEALTH CARE; RANDOMIZED CONTROLLED TRIALS; SALVAGE THERAPY; SURVIVAL ANALYSIS;

EID: 27944490449     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0284     Document Type: Review

References (10)

1. O'Shaughnessy J et al. (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 20: 2812-2823
2. Albain KS et al. (2004) Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. Proc Am Soc Clin Oncol 22: A510
3. Bell R et al. (2004) Maximizing clinical benefit with trastuzumab. Semin Oncol 31: 35-44
4. Ravdin P et al. (2003) Phase III comparison of docetaxel (D) and paclitaxel (P) in patients with metastatic breast cancer (MBC). Eur J Cancer Supplements 1: S201
5. Kelly K et al. (2001) Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 19: 3210-3218
6. Schneider A et al. (2004) Weekly irinotecan in patients with advanced non-small-cell lung cancer (NSCLC) after failure of cisplatin, taxane and gemcitabine based chemotherapy. Onkologie 27 (suppl 3): AP622
7. Du Bois A et al. (2004) Epirubicin/paclitaxe/carboplatin (TEC) vs paclitaxe/carboplatin (TC) in first-line treatment of ovarian cancer (OC) FIGO stages IIB-IV. An AGO-GINECO Intergroup phase III trial [abstract]. Proc Am Soc Clin Oncol 22: A5007
8. Tannock IF et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512
9. Goldberg RM et al. (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30
10. Tournigand C et al. (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22: 229-237